Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AGNPF exchanges : Nasdaq save search
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
ceo pharmaceuticals
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 0.37%
H: 4.5%
C: -11.69%
drug stroke pharmaceuticals research program
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2024-03-27 (Crawled : 16:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 25.81%
H: 0.0%
C: 0.0%
acquisition pharmaceuticals research program
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Published: 2024-01-31 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 5.02%
H: 13.06%
C: 11.46%
patent treat pharmaceuticals grant chinese
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
Published: 2024-01-11 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
| Email alert
Add to watchlist
patent japan fibrosis pharmaceuticals
Algernon Pharmaceuticals Announces Closing of Private Placement
Published: 2023-12-27 (Crawled : 21:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 9.2%
H: 20.51%
C: 15.38%
pharmaceuticals
Algernon Pharmaceuticals Announces Increase to Private Placement
Published: 2023-12-27 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
pharmaceuticals
Algernon Pharmaceuticals Announces Private Placement
Published: 2023-12-13 (Crawled : 01:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 3.68%
H: 0.0%
C: -5.92%
pharmaceuticals
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
Published: 2023-11-30 (Crawled : 17:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 12.32%
H: 0.0%
C: 0.0%
patent treat pharmaceuticals grant chinese nash
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2023-11-22 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 7.95%
H: 45.61%
C: 24.56%
acquisition pharmaceuticals research program
Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -8.27%
H: 0.0%
C: 0.0%
patent treatment pharmaceuticals nash
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 11.11%
H: 1.6%
C: -4.24%
patent pharmaceuticals grant nash
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -7.67%
H: 0.0%
C: 0.0%
drug stroke study phase 2
Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
Published: 2023-07-14 (Crawled : 22:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
| Email alert
Add to watchlist
pharmaceuticals financial agreement
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 3.1%
H: 0.94%
C: -3.21%
drug group pharmaceuticals program phase 2
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
Published: 2023-06-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 8.43%
H: 2.28%
C: 2.28%
conference pharmaceuticals phase 2
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
Published: 2023-06-05 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 0.0%
H: 1.14%
C: -10.27%
stroke
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
Published: 2023-05-31 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -4.89%
H: 0.0%
C: 0.0%
patent treatment pharmaceuticals
Algernon Pharmaceuticals Announces Closing of Rights Offering
Published: 2023-05-05 (Crawled : 21:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
| Email alert
Add to watchlist
offering pharmaceuticals
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
Published: 2023-04-20 (Crawled : 12:20) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 0.9%
H: 11.11%
C: 11.11%
offering pharmaceuticals
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.